CN105884720A - Buspirone hydrochloride pharmaceutical composition and medical application thereof - Google Patents
Buspirone hydrochloride pharmaceutical composition and medical application thereof Download PDFInfo
- Publication number
- CN105884720A CN105884720A CN201610260256.5A CN201610260256A CN105884720A CN 105884720 A CN105884720 A CN 105884720A CN 201610260256 A CN201610260256 A CN 201610260256A CN 105884720 A CN105884720 A CN 105884720A
- Authority
- CN
- China
- Prior art keywords
- compound
- buspirone hydrochloride
- pharmaceutical composition
- preparation
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a buspirone hydrochloride pharmaceutical composition and medical application thereof. The buspirone hydrochloride pharmaceutical composition contains buspirone hydrochloride and a natural product compound (I) novel in structure separated from dry rhizomes of Rhizoma Anemarrhenae. When the buspirone hydrochloride and the compound (I) act jointly, synoviocytes can stagnate in a cell cycle G1, so that synoviocyte proliferation is inhibited and synovitis is treated; the treatment effect of the buspirone hydrochloride and the compound (I) in joint action is superior to independent action of the buspirone hydrochloride or the compound (I). The buspirone hydrochloride pharmaceutical composition comprising the buspirone hydrochloride and the compound (I) can be developed as a drug for treating the synovitis. Compared with the prior art, the buspirone hydrochloride pharmaceutical composition has outstanding substantial characteristics and makes remarkable progress.
Description
Technical field
The invention belongs to biomedicine field, relate to the new application of buspirone hydrochloride, be specifically related to the medicine of buspirone hydrochloride
Compositions and medical usage thereof.
Background technology
Buspirone hydrochloride sheet is a kind of novel anxiolytic thing, and it is mainly subject to by serotonin (5-HT) 1A in activating brain
Body and change anxiety.
Gonarthromeningitis is a kind of sterile type inflammation, causes due to sprain of knee joint and multiple intraarticular damage.Synovial membrane
Dysfunction joint fluid can be caused cannot normally to generate and absorb, knee joint will produce hydrops.The morphologic change of synovial membrane also can
Invasion and attack knee cartilage, treatment can cause knee joint osseous arthritis not in time, there is the biggest crisis that disables.
Up to now, there is not yet the dependency report of buspirone hydrochloride and pharmaceutical composition thereof and synovitis.
Summary of the invention
It is an object of the invention to provide the pharmaceutical composition of a kind of buspirone hydrochloride, containing hydrochloric acid fourth spiral shell in this pharmaceutical composition
Cyclic ketones and the natural product of a kind of novel structure, buspirone hydrochloride and this natural product can be with Synergistic treatment synovitis.
The above-mentioned purpose of the present invention is achieved by techniques below scheme:
A kind of compound (I) with following structural formula,
The pharmaceutical composition of a kind of buspirone hydrochloride, including buspirone hydrochloride, compound as claimed in claim 1 (I)
Pharmaceutically acceptable carrier, is prepared as the dosage form needed.
Further, pharmaceutically acceptable carrier includes diluent, excipient, filler, binding agent, wetting agent, collapses
Solve agent, absorption enhancer, surfactant, absorption carrier or lubricant.
Further, described dosage form include tablet, capsule, oral liquid, suck agent, granule, electuary, pill, powder,
Unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, spray, drop or patch.
The preparation method of above-claimed cpd (I), comprises following operating procedure: the dry rhizome of the Rhizoma Anemarrhenae is pulverized by (a), uses
75～85% alcohol heat reflux extract, united extraction liquid, be concentrated into without alcohol taste, use petroleum ether, ethyl acetate and water saturated successively
N-butanol extraction, respectively obtains petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract；In (b) step (a)
N-butyl alcohol takes thing macroporous resin remove impurity, first with 8 column volumes of 25% ethanol elution, then with 12 cylinders of 70% ethanol elution
Long-pending, collect 70% eluent, concentrating under reduced pressure obtains 70% ethanol elution concentrate；C in () step (b), 70% ethanol elution is dense
Contracting thing purification on normal-phase silica gel separates, and obtains with the methylene chloride-methanol gradient elution that volume ratio is 85:1,45:1,25:1 and 15:1 successively
To 4 components；D in () step (c), component 4 separates further by purification on normal-phase silica gel, be 20:1,15:1 by volume ratio successively
3 components are obtained with the methylene chloride-methanol gradient elution of 1:1；Component 2 octadecylsilane key in (e) step (d)
The reverse phase silica gel closed separates, and with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 72%, collects 10～16 column volumes and washes
De-liquid, eluent is concentrated under reduced pressure to give compound (I).
Further, in the preparation method of compound (I), step (a) is extracted with 80% alcohol heat reflux, united extraction liquid.
Further, in the preparation method of compound (I), described macroporous resin is D101 type macroporous adsorbent resin.
Further, in the preparation method of compound (I), step (a) replace ethyl acetate to extract with dichloromethane,
Obtain dichloromethane extract.
The above-claimed cpd (I) application in the medicine of preparation treatment synovitis.
The application in the medicine of preparation treatment synovitis of the pharmaceutical composition of above-mentioned buspirone hydrochloride.
Advantages of the present invention:
Containing buspirone hydrochloride and a kind of dry rhizome from the Rhizoma Anemarrhenae in the pharmaceutical composition of the buspirone hydrochloride that the present invention provides
When the natural product of the novel structure of middle isolated, buspirone hydrochloride and this natural product independent role, synovitis is had
Therapeutical effect；During the two synergy, the therapeutic effect of synovitis is improved further, the medicine for the treatment of synovitis can be developed into
Thing.The present invention compared with prior art has prominent substantive distinguishing features and significantly progress.
Detailed description of the invention
Further illustrate the essentiality content of the present invention below in conjunction with embodiment, but do not limit scope with this.To the greatest extent
The present invention is explained in detail by pipe with reference to preferred embodiment, it will be understood by those within the art that, can be to the present invention
Technical scheme modify or equivalent, without deviating from the spirit and scope of technical solution of the present invention.
Embodiment 1: compound (I) separates preparation and structural identification
Separation method: the dry rhizome (2kg) of the Rhizoma Anemarrhenae is pulverized by (a), extracts (15L × 3 time) with 80% alcohol heat reflux,
United extraction liquid, is concentrated into without alcohol taste (3L), successively with petroleum ether (3L × 3 time), ethyl acetate (3L × 3 time) and
Water saturated n-butyl alcohol (3L × 3 time) extracts, and respectively obtains petroleum ether extract, acetic acid ethyl ester extract and n-butanol extraction
Thing；B acetic acid ethyl ester extract D101 type macroporous resin remove impurity in () step (a), first with 8 posts of 25% ethanol elution
Volume, then with 12 column volumes of 70% ethanol elution, collect 70% eluent, concentrating under reduced pressure obtains 70% ethanol elution concentrate；
In (c) step (b) 70% ethanol elution concentrate with purification on normal-phase silica gel separate, successively with volume ratio be 85:1 (10 column volumes),
45:1 (8 column volumes), 25:1 (10 column volumes) and the methylene chloride-methanol gradient elution of 15:1 (8 column volumes)
Obtain 4 components；D in () step (c), component 4 separates further by purification on normal-phase silica gel, be 20:1 (10 by volume ratio successively
Individual column volume), the methylene chloride-methanol gradient elution of 15:1 (8 column volumes) and 1:1 (6 column volumes) obtain 3 groups
Point；E reverse phase silica gel that in () step (d), component 2 is bonded by octadecylsilane separates, and is 72% by concentration expressed in percentage by volume
Methanol aqueous solution isocratic elution, collect 10～16 column volume eluents, eluent is concentrated under reduced pressure to give compound (I)
(260mg, HPLC normalization purity is more than 98%).
Structural identification: colourless crystallization, HR-ESIMS shows [M+H]+For m/z 335.2174, molecule can be obtained in conjunction with nuclear-magnetism feature
Formula is C20H30O4, degree of unsaturation is 6.Hydrogen nuclear magnetic resonance modal data δH(ppm, pyridine-d5, 500MHz): H-1 (6.04,
Dd, J=6.7,12.1Hz), H-2 (6.52, dd, J=12.1,9.5Hz), H-3 (7.13, d, J=9.5Hz), H-5a
(3.23, d, J=15.6Hz), H-5b (2.98, dd, J=15.6,9.3Hz), H-6 (5.06, dd, J=9.3,1.4Hz),
H-7 (1.87, m), H-8 (1.53, m), H-9a (2.02, m), H-9b (1.61, m), H-10 (1.96, m),
H-11 (1.77, m), H-12 (0.85, d, J=5.9Hz), H-13 (1.13, d, J=6.8Hz), H-14 (1.20, d,
J=6.8Hz), H-2 ' (2.73, m), H-3 ' (4.25, m), H-4 ' (1.33, d, J=6.1Hz), H-5 ' (1.18, d,
J=7.4Hz)；Carbon-13 nmr spectra data δC(ppm, pyridine-d5, 125MHz): 133.2 (CH, 1-C), 127.4
(CH, 2-C) 135.3 (CH, 3-C), 122.5 (C, 4-C), 28.3 (CH2, 5-C), 77.4 (CH, 6-C),
52.7 (CH, 7-C), 27.7 (CH, 8-C), 35.2 (CH2, 9-C), 42.8 (CH, 10-C), 26.4 (CH,
11-C), 22.1 (CH3, 12-C), 23.8 (CH3, 13-C), 18.4 (CH3, 14-C), 171.2 (C, 15-C),
209.4 (C, 1 '-C), 48.7 (CH, 2 '-C), 70.3 (CH, 3 '-C), 22.0 (CH3, 4 '-C), 13.7 (CH3,
5’-C).1756cm in infrared spectrum-1236nm absorption band during absorption band and UV compose shows that this compound contains α, β-no
Saturated lactone structure, the 3353cm in infrared spectrum-1、1715cm-1With 1624cm-1Absorption band show structure exists hydroxyl,
Ketone group and α, β-unsaturated conjugated system.13C-NMR, DEPT and hsqc spectrum show 20 carbon signals, including five
Methyl, two methylene, ten methines (two company's oxygen carbon and three alkene carbon), and three quaternary carbon (two carbonyl carbon
With an alkene carbon), in conjunction with insatiable hunger sum, function above structure shows that this compound is twin nuclei.1H-NMR composes combination
Hsqc spectrum shows five methyl proton signal δH0.85 (3H, d, J=5.9Hz), 1.13 (3H, d, J=6.8Hz), 1.20
(3H, d, J=6.8Hz), 1.33 (3H, d, J=6.1Hz), 1.18 (3H, d, J=7.4Hz), three conjugated alkenes
Proton signal δH6.04 (1H, dd, J=6.7,12.1Hz), 6.52 (1H, dd, J=12.1,9.5Hz) with 7.13 (1H,
D, J=9.5Hz), two company oxygen methine proton signal δH5.06 (1H, dd, J=9.3,1.4Hz) and 4.25 (1H, m).1H-1There is H-1/H-2/H-3, H in H COSY spectrum2-5/H-6/H-7/H-8/H2-9/H-10、H-7/H-11/H3-12、H-11/H3-13
And H-8/H3-14 coherent signals, H-2, H of display in composing in conjunction with HMBC2-9 and H-10 and C-1, H-2, H2-5 and
H-6 Yu C-4 coherent signal can build germacrane sesquiterpene skeleton.1H-1H in H COSY spectrum3-5’/H-2’/H-3’/H3-4’
During coherent signal and HMBC compose, H-2 ' and C-1 ', C-3 ' and C-5 ' and H-3 ' and C-2 ' and C-4 ' coherent signal can build
O-3 '-O-hydroxyl-2 '-espeleton substrate section, HMBC spectrum H-10 and C-1 ' coherent signal shows this fragment and germacrane simultaneously
The position that type sesquiterpene skeleton connects.Additionally HMBC composes H-3, H2-5 and H-6 Yu C-15 coherent signal hint C-6 and C-15
Between exist a lactonic ring structure.In NOESY spectrum, it is assumed that H-8 is beta comfiguration, then H-8 Yu H-10 coherent signal table
Bright H-10 is also beta comfiguration, therefore, O-3 '-O-hydroxyl-2 '-espeleton base should be α configuration.Comprehensive hydrogen spectrum, carbon spectrum, HMBC
Spectrum and NOESY compose, and document is about correlation type nuclear magnetic data, can substantially determine that this compound is as follows, three-dimensional structure
Type is determined by ECD test further, and theoretical value is basically identical with experiment value.
This compound chemical formula and carbon atoms numbered are as follows:
Embodiment 2: pharmacological action
1. materials and methods
1.1 animal
Select male Wistar rat (Tongji Medical College, Huazhong Science and Technology Univ.'s animal experimental center provides), about body weight 120g.
1.2 reagent and sample
Buspirone hydrochloride is purchased from Nat'l Pharmaceutical & Biological Products Control Institute.Compound (I) is made by oneself, and preparation method is shown in embodiment 1.
II Collagen Type VI (Sigma Co., USA), incomplete Freund's adjuvant (Sigma company), RPMI-1640 (GIBCO company).
1.3 instrument
U.S. nurie CO2Incubator (NU4750 type), Japan Olympic Pasteur's inverted fluorescence microscope (CKX41 type),
U.S.'s Beckman Coulter flow cytometer (EPICSXL type), Japan's transmission electron microscope (Hitachi's H-7500 type).
1.4 rat model preparations and cell packet
II Collagen Type VI is dissolved in the glacial acetic acid of 0.1mmol/L by the preparation of Collagen-induced Arthritis (CIA) rat model
(the final concentration of 2g/L of II Collagen Type VI), 4 DEG C overnight.Then dropped in cold equivalance incomplete Freund's adjuvant the most newborn
Change.By this Emulsion every rat intradermal injection 0.5ml, point 4, back and tail heel 1 point.Same method booster injection after 7 days
1 time.Every day every rat articular is marked according to joint swelling index marking system, be divided into 0～4 point: 0 point, without red and swollen；
1 point, little toe redness and swelling of joints；2 points of toe joints and pedal swelling；3 points, the sufficient pawl swelling below ankle joint；4 points, including ankle
Whole foot pawl swelling within joint.The exponential accumulation in each joint is scored, is the arthritis index of every rat.
The In vitro culture of synovial cell causes after inflammation the 25th day, and the rat of morbidity is put to death in dislocation, obtains synovial tissue under aseptic condition,
Cut into about 1mm3Fragment, the II Collagenase Type 37 DEG C digestion 6～7h of 0.5mg/ml, 1200r/m is centrifuged 8min, adds 1640
Culture fluid [is divided into 5 groups: model control group, positive controls, buspirone hydrochloride group, compound (I) group, hydrochloric acid fourth
Spirocyclic ketone and compound (I) compositions group, often organize all containing 10% hyclone；Positive controls is possibly together with 1.0 × 10-6mol/L
Methotrexate, buspirone hydrochloride group is possibly together with 2.0 × 10-6The buspirone hydrochloride of mol/L, compound (I) group also contains
Have 2.0 × 10-6The compound (I) of mol/L, buspirone hydrochloride and compound (I) compositions group are possibly together with 1.0 × 10-6mol/L
Buspirone hydrochloride and 1.0 × 10-6The compound (I) of mol/L], it is placed in 37 DEG C of 5%CO2Cultivate in incubator, digestion
Pass on, with the 3rd～5 generation cells.
1.5 flow cytomery synovial cell's cycles
Collect cell, blow and beat into single cell suspension with PBS is resuspended, be added slowly in 5ml 75% ethanol of pre-cooling, 4 DEG C
Fix overnight；With PBS, its concentration is adjusted to 5 × 106Individual/ml, then takes 400 μ l, adds RAase 20ml, 37 DEG C of water-bath 30min；
Add PI 100 μ l, lucifuge dyeing 20min, 300 mesh nylon net filters, flow cytometer.
1.6 statistical method
Experimental data mean ± standard deviation (x ± s) represents, application SPSS18.0 version statistical software carry out one factor analysis of variance and
T checks, statistically significant for difference with P ＜ 0.05.
2. experimental result
Flow cytometer periodicity analysis results shows, compares with model group, and the positive controls G1 phase increases, and the S phase reduces, difference
There is statistical significance (P < 0.05)；Buspirone hydrochloride and compound (I) compositions group G1 phase substantially increase (P < 0.01),
The S phase significantly reduces (P < 0.01)；Buspirone hydrochloride group and compound (I) group G1 phase increase (P < 0.05), and the S phase subtracts
Few (P < 0.05).
The table 1 impact on CIA lymphocyte of adjurant arthritis rat cell cycle
| Group | The G1 phase (%) | The S phase (%) |
| Model control group | 65.50±2.26 | 12.82±2.81 |
| Positive controls | 80.24±2.33 | 3.52±0.73 |
| Buspirone hydrochloride group | 78.15±3.05 | 3.88±0.74 |
| Compound (I) group | 79.24±2.49 | 3.60±0.78 |
| Buspirone hydrochloride and compound (I) compositions group | 83.95±5.02 | 1.34±0.58 |
In rheumatoid arthritis (RA) joint injury and reconstructed tissue, synovial cell is target cell, also by number of ways
Becoming participant, the change of its function plays vital effect in the process of disease, and fibroblast-like synoviocyte is synovial membrane
The main component of tissue, take part in articular cartilage damage and periarticular bone destruction, so it is thin to suppress into fiber-like synovial membrane
Born of the same parents' propagation is one of means for the treatment of RA.
The above results shows, during compound (I) synergy that buspirone hydrochloride and the present invention provide, can make synovial cell
It is stuck in the cell cycle G1 phase, thus suppresses synovial cell proliferation, treat synovitis；Therapeutic effect is better than buspirone hydrochloride
Or compound (I) independent role.Buspirone hydrochloride and compound (I) compositions can be developed into the medicine for the treatment of synovitis.
The effect of above-described embodiment indicates that the essentiality content of the present invention, but does not limit protection scope of the present invention with this.
It will be understood by those within the art that, technical scheme can be modified or equivalent, and not take off
Essence and protection domain from technical solution of the present invention.
Claims (10)
1. a compound (I) with following structural formula,
2. the pharmaceutical composition of a buspirone hydrochloride, it is characterised in that: include buspirone hydrochloride, such as claim 1 institute
The compound (I) stated and pharmaceutically acceptable carrier, be prepared as the dosage form needed.
The pharmaceutical composition of buspirone hydrochloride the most according to claim 2, it is characterised in that: pharmaceutically acceptable
Carrier include diluent, excipient, filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant,
Absorption carrier or lubricant.
The pharmaceutical composition of buspirone hydrochloride the most according to claim 2, it is characterised in that: described dosage form include tablet,
Capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution
Agent, injection, suppository, spray, drop or patch.
5. the preparation method of the compound (I) described in claim 1, it is characterised in that comprise following operating procedure: (a)
The dry rhizome of the Rhizoma Anemarrhenae is pulverized, with 75～85% alcohol heat reflux extraction, united extraction liquid, is concentrated into without alcohol taste, uses stone successively
Oil ether, ethyl acetate and water saturated n-butanol extraction, respectively obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol
Extract；B in () step (a), n-butyl alcohol takes thing macroporous resin remove impurity, first with 8 column volumes of 25% ethanol elution, then
With 12 column volumes of 70% ethanol elution, collecting 70% eluent, concentrating under reduced pressure obtains 70% ethanol elution concentrate；(c) step
Suddenly in (b), 70% ethanol elution concentrate purification on normal-phase silica gel separates, and is 85:1,45:1,25:1 and 15:1 by volume ratio successively
Methylene chloride-methanol gradient elution obtain 4 components；D in () step (c), component 4 separates further by purification on normal-phase silica gel,
3 components are obtained successively with the methylene chloride-methanol gradient elution that volume ratio is 20:1,15:1 and 1:1；(e) step (d)
The reverse phase silica gel that middle component 2 is bonded by octadecylsilane separates, and washes with the methanol aqueous solution that concentration expressed in percentage by volume is 72% is isocratic
De-, collect 10～16 column volume eluents, eluent is concentrated under reduced pressure to give compound (I).
The preparation method of compound the most according to claim 5 (I), it is characterised in that: step (a) 80% second
Alcohol circumfluence distillation, united extraction liquid.
The preparation method of compound the most according to claim 5 (I), it is characterised in that: described macroporous resin is D101
Type macroporous adsorbent resin.
The preparation method of compound the most according to claim 5 (I), it is characterised in that: step (a) is used dichloromethane
Alkane replaces ethyl acetate to extract, and obtains dichloromethane extract.
9. the application in the medicine of preparation treatment synovitis of the compound (I) described in claim 1.
10. the pharmaceutical composition of the arbitrary described buspirone hydrochloride of claim 2～4 is in the medicine of preparation treatment synovitis
Application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610260256.5A CN105884720A (en) | 2016-04-23 | 2016-04-23 | Buspirone hydrochloride pharmaceutical composition and medical application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610260256.5A CN105884720A (en) | 2016-04-23 | 2016-04-23 | Buspirone hydrochloride pharmaceutical composition and medical application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105884720A true CN105884720A (en) | 2016-08-24 |
Family
ID=56704802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610260256.5A Pending CN105884720A (en) | 2016-04-23 | 2016-04-23 | Buspirone hydrochloride pharmaceutical composition and medical application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105884720A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105713065A (en) * | 2016-04-23 | 2016-06-29 | 何淑琼 | Azathioprine pharmaceutical composition and medical application thereof |
| CN105777672A (en) * | 2016-03-16 | 2016-07-20 | 郭根松 | Medical composition of amlodipine besylate and ventricular remodeling effect of medical composition |
| CN106279344A (en) * | 2016-08-14 | 2017-01-04 | 吴芊葭 | A kind of native compound separated from Radix Saposhnikoviae and preparation method thereof, medical applications |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1909911A (en) * | 2003-10-01 | 2007-02-07 | 浩鼎生技公司 | Treatment of a condition in a mammal with adminisration of aminosugar and uses thereof |
| CN105753878A (en) * | 2016-03-31 | 2016-07-13 | 河南省洛正制药厂 | Quality control method for synovitis tablets |
| CN105859659A (en) * | 2016-04-27 | 2016-08-17 | 周飞燕 | Medicine composition of buspirone hydrochloride and medical application thereof |
| CN106109461A (en) * | 2016-06-23 | 2016-11-16 | 崔坤峰 | The pharmaceutical composition of bezafibrate and the application in rheumatoid arthritis thereof |
-
2016
- 2016-04-23 CN CN201610260256.5A patent/CN105884720A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1909911A (en) * | 2003-10-01 | 2007-02-07 | 浩鼎生技公司 | Treatment of a condition in a mammal with adminisration of aminosugar and uses thereof |
| CN105753878A (en) * | 2016-03-31 | 2016-07-13 | 河南省洛正制药厂 | Quality control method for synovitis tablets |
| CN105859659A (en) * | 2016-04-27 | 2016-08-17 | 周飞燕 | Medicine composition of buspirone hydrochloride and medical application thereof |
| CN106109461A (en) * | 2016-06-23 | 2016-11-16 | 崔坤峰 | The pharmaceutical composition of bezafibrate and the application in rheumatoid arthritis thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105777672A (en) * | 2016-03-16 | 2016-07-20 | 郭根松 | Medical composition of amlodipine besylate and ventricular remodeling effect of medical composition |
| CN105713065A (en) * | 2016-04-23 | 2016-06-29 | 何淑琼 | Azathioprine pharmaceutical composition and medical application thereof |
| CN106279344A (en) * | 2016-08-14 | 2017-01-04 | 吴芊葭 | A kind of native compound separated from Radix Saposhnikoviae and preparation method thereof, medical applications |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105859659A (en) | Medicine composition of buspirone hydrochloride and medical application thereof | |
| WO2017220041A2 (en) | Bezafibrate pharmaceutical composition and application thereof in rheumatoid arthritis | |
| CN106083771A (en) | The pharmaceutical composition of carbidopa and the medical usage for the treatment of liver cancer thereof | |
| CN105884720A (en) | Buspirone hydrochloride pharmaceutical composition and medical application thereof | |
| EP1282613A1 (en) | A pharmaceutical composition containing the extract of saururus chinensis baill useful as and anticancer agent and a process for the preparation thereof | |
| CN108689851B (en) | Tiglic alkane type diterpene compound and preparation method and application thereof | |
| CN106008543A (en) | Novel diterpenoid compound and preparation method thereof | |
| CN105949159A (en) | Medicine composition with pramipexole dihydrochloride and application of medicine composition to treating migraine | |
| CN105693668A (en) | Pharmaceutical composition of clofazimine and medical application of composition | |
| CN105801526A (en) | Drug composition of cyproheptadine hydrochloride and application thereof in biomedicine | |
| CN105777685A (en) | Pharmaceutical composition of felodipine and pharmaceutical application of pharmaceutical composition | |
| CN105477004A (en) | Application of compound or salt thereof in preparing nerve-protecting drugs | |
| CN105820144A (en) | Pharmaceutical composition of cefdinir and medical application thereof | |
| CN105801540A (en) | Carteolol hydrochloride medicine composition and medicine purpose thereof | |
| CN105837541A (en) | Pharmaceutical composition of benproperine phosphate and application of pharmaceutical composition in biological medicines | |
| CN105523937A (en) | Diterpene compound with medical application and preparation method thereof | |
| CN106083800A (en) | The pharmaceutical composition of chlorprothixene and the protective effect to cerebral ischemia reperfusion injury | |
| CN105820053A (en) | Pharmaceutical composition of cefalexin and application of pharmaceutical composition in biological medicine | |
| CN105497044A (en) | Pharmaceutical composition for treatment of diseases or illness affected by neuronal injury | |
| CN105687179A (en) | Application of catclaw buttercup root tuber extract as composition in preparing medicine for treating cancer | |
| CN105534968A (en) | Application of diterpenoid compound to preparation of drug for treating prostate cancer | |
| CN105273035A (en) | Compound and preparation method thereof | |
| CN105503782A (en) | Protoilludanes type sesquiterpenoid compound and preparation method and medical application thereof | |
| CN111529515B (en) | Application of 12, 15-dioxo-alpha-cnidiene in pharmacy | |
| CN106117034A (en) | A kind of highly oxidized sesquiterpenoids and preparation method thereof and medical usage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160824 |